Oral Vancomycin Therapy for Primary Sclerosing Cholangitis: Beacon of Hope or a Dead End?
Author:
- 12 October 2026
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Abstract
Was not provided for this article.Keywords
This publication has 11 references indexed in Scilit:
- Oral Vancomycin Is an Effective Therapy in Adult Patients With Inflammatory Bowel Disease and Primary Sclerosing CholangitisGastro Hep Advances, 2026
- Oral vancomycin for primary sclerosing cholangitis and associated inflammatory bowel disease – paving a path forwardExpert Review of Gastroenterology & Hepatology, 2026
- Outcomes of oral vancomycin therapy in children with atypical ulcerative colitis with or without confirmed primary sclerosing cholangitis: a real-world observational studyBMJ Open Gastroenterology, 2025
- Open Label Vancomycin in Primary Sclerosing Cholangitis-Inflammatory Bowel Disease: Improved Colonic Disease Activity and Associations With Changes in Host–Microbiome–Metabolomic SignaturesJournal of Crohn's and Colitis, 2024
- Oral Vancomycin, Ursodeoxycholic Acid, or No Therapy for Pediatric Primary Sclerosing Cholangitis: A Matched AnalysisHepatology, 2021
- Open-label prospective therapeutic clinical trials: oral vancomycin in children and adults with primary sclerosing cholangitisScandinavian Journal of Gastroenterology, 2020
- Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis ‐ a pilot studyAlimentary Pharmacology & Therapeutics, 2013
- Improvement of serum alkaline phosphatase to <1.5 upper limit of normal predicts better outcome and reduced risk of cholangiocarcinoma in primary sclerosing cholangitisJournal of Hepatology, 2013
- Immunomodulatory Effect of Vancomycin on Treg in Pediatric Inflammatory Bowel Disease and Primary Sclerosing CholangitisJournal of Clinical Immunology, 2012
- Biliary Epithelial Cell Antibodies Link Adaptive and Innate Immune Responses in Primary Sclerosing CholangitisGastroenterology, 2007